Equities

Silk Road Medical Inc

Silk Road Medical Inc

Actions
  • Price (USD)22.27
  • Today's Change0.23 / 1.04%
  • Shares traded563.94k
  • 1 Year change-29.21%
  • Beta1.5183
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Silk Road Medical, Inc. is a medical device company that is focused on reducing the risk of stroke and its impact. The Company has developed an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. Its product portfolio consists of five single-use components: ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014'' Guidewire and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. It manufactures ENROUTE NPS and ENROUTE NPS PLUS, or its ENROUTE NPS products, at its facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of over 35,000 square feet of space for its production and distribution operations.

  • Revenue in USD (TTM)185.49m
  • Net income in USD-53.42m
  • Incorporated2007
  • Employees474.00
  • Location
    Silk Road Medical Inc1213 Innsbruck DrSUNNYVALE 94089-1317United StatesUSA
  • Phone+1 (650) 566-9060
  • Fax+1 (302) 655-5049
  • Websitehttps://silkroadmed.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Varex Imaging Corp855.80m41.90m611.46m2.30k24.751.067.940.71450.6040.60416.1814.100.70081.945.50356,583.303.470.99134.031.1832.3931.704.951.362.372.570.4292--3.962.9359.0818.880.2924--
Fulgent Genetics Inc287.53m-165.95m638.88m1.18k--0.5648--2.22-5.57-5.579.6437.800.2206--6.01242,846.30-13.2916.70-14.1618.3737.4767.89-60.2529.06----0.00140.00-53.2768.41-217.03--57.08--
Paragon 28 Inc225.44m-54.02m652.83m430.00--3.97--2.90-0.6536-0.65362.731.980.69560.54055.82524,267.40-16.67---20.52--79.21---23.96--1.78-6.450.4018--19.30--28.94------
Pulse Biosciences Inc0.00-42.55m659.39m56.00--18.17-----0.8152-0.81520.000.65710.00----0.00-71.28-93.21-79.29-104.99-------12,332.25----0.00---100.00--27.85---15.20--
Embecta Corp1.13bn70.20m782.58m2.20k11.16--7.400.6911.221.2219.62-13.350.942.5115.86514,772.705.83--8.06--65.57--6.20--1.791.511.89---0.7703---68.52------
Cytek Biosciences Inc200.79m-11.51m783.70m637.00--2.00--3.90-0.0856-0.08561.502.990.3951.444.30297,020.70-2.26---2.54--55.48---5.73--6.01--0.0086--17.67---571.58------
Orthopediatrics Corp161.83m-21.97m789.93m247.00--2.11--4.88-0.9647-0.96477.1115.740.37480.42475.13655,178.10-5.09-5.40-5.62-5.9374.0775.09-13.58-15.921.99--0.0271--21.6220.91-1,767.25--28.29--
Atrion Corp176.67m18.72m830.68m712.0044.393.4324.254.7010.6310.63100.32137.460.67941.567.93248,127.807.2011.967.6312.6233.7741.9910.6019.053.06--0.0042.42-7.732.12-44.55-10.744.9811.27
Silk Road Medical Inc185.49m-53.42m878.41m474.00--5.96--4.74-1.37-1.374.763.730.72472.087.87391,322.80-20.87-29.02-22.75-32.9873.3172.91-28.80-46.849.62--0.34--27.7738.66-1.33---7.92--
Avanos Medical Inc680.10m-1.60m934.60m3.77k--0.763821.341.37-0.0315-1.3314.6226.650.40051.625.48180,350.00-0.0942-0.6527-0.1055-0.733856.3354.45-0.2353-1.601.474.850.1257---1.580.6357-146.05---18.37--
Artivion Inc368.21m-9.58m991.61m1.50k--3.3672.772.69-0.2615-0.26158.647.070.47791.645.37245,470.70-1.25-2.20-1.33-2.3664.7565.51-2.61-5.344.262.260.5176--12.826.14-60.09--5.13--
BioLife Solutions Inc137.30m-62.93m1.01bn409.00--3.00--7.34-1.43-1.433.107.300.32382.175.61335,687.00-14.84-13.76-16.52-15.0432.9736.76-45.84-42.991.77-32.080.0717---11.4348.6552.49--86.35--
AtriCure Inc414.60m-37.23m1.10bn1.20k--2.41--2.65-0.8005-0.80058.929.430.70591.708.21345,501.70-6.34-3.72-7.08-4.1075.2674.36-8.98-7.642.83-10.270.1212--20.8414.6434.49--46.56--
Coretag Inc0.00-34.52k1.13bn0.00---------0.3806-0.38060.00-0.98010.00-------3,303.35--------------------------10.95------
MiMedx Group Inc334.51m71.52m1.16bn895.0020.847.4414.543.460.37670.33932.151.061.722.826.58373,754.2041.80-4.1453.13-5.9083.5083.6124.36-2.702.719.000.111--20.03-2.19310.29---26.47--
Data as of May 22 2024. Currency figures normalised to Silk Road Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

54.85%Per cent of shares held by top holders
HolderShares% Held
Wasatch Advisors, Inc.as of 31 Mar 20244.55m11.61%
Capital Research & Management Co. (World Investors)as of 31 Mar 20243.11m7.94%
The Vanguard Group, Inc.as of 31 Mar 20242.85m7.27%
BlackRock Fund Advisorsas of 31 Mar 20242.72m6.95%
D. E. Shaw & Co. LPas of 31 Mar 20241.60m4.08%
Bellevue Asset Management AGas of 31 Mar 20241.52m3.88%
Morgan Stanley & Co. LLCas of 31 Mar 20241.52m3.87%
BAMCO, Inc.as of 31 Mar 20241.50m3.83%
Tri Locum Partners LPas of 31 Mar 20241.08m2.77%
SSgA Funds Management, Inc.as of 31 Mar 20241.04m2.65%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.